Healthcare
BeOne Medicines Ltd.(ONC)
Live Price
Offline$270.15
+2.84% today
1Y Change
+3.74%
Window
Jun 25, 2025 β Jun 24, 2026
- Market Cap
- $35.97B
- Revenue Growth
- +40.2%
- EPS Growth
- +658.7%
- Dividend Yield
- 0.0%
Coverage: 251 bars Β· Jun 25, 2025 β Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
BeOne Medicines Ltd. (ONC) is a Healthcare stock with a market cap of $35.97B and listed on NASDAQ. The stock last traded around $270.15 and up 3.7% across the available one-year price window (Jun 25, 2025 β Jun 24, 2026). Baseline metrics include revenue growth of +40.2%, EPS growth of +658.7%, a dividend yield of 0.0%. What stands out right now is revenue +40.2%, EPS +658.7%, free cash flow +240.6% with operating margin 8.4% and ROIC 4.8%. Valuation already assumes a fairly strong business story at P/E 172.0 and price/sales 6.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines ONC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+40.2% vs +7.6% peer median
Operating Margin
Below sector median
+8.4% vs +19.4% peer median
P/E
Above sector median
172.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +40.2% and EPS at +658.7%, with operating margin around 8.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.9% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | β | +1.2% | +1.0% | -10.7% |
2026 Feb 26, 2026 | -63.8% | -1.7% | -9.1% | -14.1% |
2025 Nov 6, 2025 | +51.4% | -3.7% | +10.8% | -2.8% |
Benchmark Edge
ONC vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ONC
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ONC Max Drawdown
-31.05%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ONC and SPY.
Company Overview
BeOne Medicines Ltd.
NASDAQ Global Market
BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusettsβwith operations spanning over 45 countries across six continentsβthe company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China. The companyβs strategy combines internal R&D with the development of assets sourced from external partnerships, driving a robust pipeline across hematologic malignancies and solid tumors.
- Leadership
- John V. Oyler
- IPO Date
- Feb 2, 2016
- Employees
- 11.0k
- Region
- US
- Reporting Currency
- USD
- Investor Line
- 345-949-4123
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 172.0
- EV/EBITDA
- 60.3
- Price/Sales
- 6.7
- Price/Book
- 11.4
Growth
- Revenue
- +40.2%
- EPS
- +658.7%
- Free Cash Flow
- +240.6%
Profitability
- Gross Margin
- 86.9%
- Operating Margin
- 8.4%
- Net Margin
- 5.4%
- ROE
- 7.3%
- ROIC
- 4.8%
Balance Sheet
- Debt/Equity
- 0.46
- Current Ratio
- 3.41
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.